Can vemurafenib/zobovo be classified as a targeted therapy?

Vemurafenib/zobovo(Vemurafenib) is a typical targeted tumor treatment drug. Its core mechanism is to inhibit the BRAF V600 mutant protein in tumor cells, thereby blocking the activation of abnormal MAPK signaling pathways and inhibiting cancer cell proliferation. Unlike traditional chemotherapy drugs that kill rapidly dividing cells non-selectively, vemurafenib was originally designed to target "driver mutations" at the molecular level to achieve specific intervention, so it is widely classified as a molecular targeted drug. Its target BRAF gene mutation has been found in a variety of malignant tumors such as melanoma, colorectal cancer, and thyroid cancer, among which the V600E mutation is the most representative. The research and development of vemurafenib has promoted medical breakthroughs in the field of skin cancer, allowing patients to select suitable targeted solutions through genetic testing and achieve personalized treatment.

In clinical application, the targeting characteristics of vemurafenib are not only reflected in the mechanism of action, but also in the therapeutic response mode. Patients with positive BRAF V600 mutations usually see tumor shrinkage or stable disease after treatment. However, if the tumor is BRAF wild-type, the MAPK pathway may be reversely activated and promote tumor growth. Therefore, molecular testing must be performed before using vemurafenib to ensure that the drug matches the target.

From a pharmacological perspective, vemurafenib is a small molecule kinase inhibitor whose structure can competitively bind to the ATP binding site ofBRAF kinase, thereby blocking the downstream MEK-ERK signaling chain. Its precise intervention capabilities make it an important representative of molecular targeted therapy systems. Currently, BRAF inhibitors including vemurafenib have become one of the standard treatments for advanced melanoma, and are often combined with MEK inhibitors to delay the development of drug resistance.

In general, the emergence of vemurafenib marks the transition of melanoma treatment from the "chemotherapy era" to the "precision targeting era". It not only improves the survival period of patients, but also improves the quality of life, so it is clearly classified as a targeted therapy drug.

Reference: https://www.drugs.com/mtm/vemurafenib.html